ASCO 2016 melanoma highlights: immunotherapy developments and further data on checkpoint inhibitors
Combined treatment with BRAF and MEK inhibitors in metastatic melanomas with BRAF mutations
Rodabe N. Amaria
Striking results from the PACIFIC trial
What is the future for patients with metastatic sarcoma?
Breelyn A. Wilky
ESMO guidelines for thymic cancer management